19708 Federal Register / Vol. 63, No. 76 /Tuesday, April 21, 1998 / Notices

DEPARTMENT OF COMMERCE

Foreign-Trade Zones Board

[Docket No. 6–98]

Foreign-Trade Zone 37—Orange

County, New York, Area, Application

for Expansion; Extension of Public

Comment Period

The comment period for the above

case, submitted by the County of

Orange, New York, requesting authority

to expand its zone in the Orange

County, New York, area (63 FR 6890, 2/

11/98), is extended to May 13, 1998, to

allow interested parties additional time

in which to comment on the proposal.

Comments in writing are invited

during this period. Submissions should

include three (3) copies. Material

submitted will be available at: Office of

the Executive Secretary, Foreign-Trade

Zones Board, U.S. Department of

Commerce, Room 3716, 14th &

Pennsylvania Avenue, NW, Washington,

DC 20230.

Dated: April 8, 1998.

Dennis Puccinelli,

Acting Executive Secretary.

[FR Doc. 98–10414 Filed 4–20–98; 8:45 am]

BILLING CODE 3510–DS–P

DEPARTMENT OF COMMERCE

Foreign-Trade Zones Board

[Docket 20–98]

Foreign-Trade Zone 61—San Juan,

Puerto Rico, Application for Subzone,

Pfizer Pharmaceuticals, Inc.

(Pharmaceutical Products),

Barceloneta, Puerto Rico

An application has been submitted to

the Foreign-Trade Zones Board (the

Board) by the Commercial and Farm

Credit and Development Corporation of

Puerto Rico, grantee of FTZ 61,

requesting special-purpose subzone

status for the pharmaceutical

manufacturing plant of Pfizer

Pharmaceuticals, Inc. (Pfizer), in

Barceloneta, Puerto Rico. The

application was submitted pursuant to

the provisions of the Foreign-Trade

Zones Act, as amended (19 U.S.C. 81a–

81u), and the regulations of the Board

(15 CFR part 400). It was formally filed

on April 13, 1998.

Pfizer is a wholly-owned subsidiary of

Pfizer Inc. (U.S.), which comprises three

global businesses—Health Care,

Consumer Health Care and Animal

Health.

Pfizer’s Barceloneta plant (420,000 sq.

ft. on 95 acres + 150-acre adjacent area)

is located at Road 2, KM 58.2,

Barceloneta, Puerto Rico, some 45 miles

west of San Juan. The facility (with

some 1,000 employees) produces

finished pharmaceutical products,

primarily SINEQUAN, DIABINESE,

ANTIVERT, MINIPRESS, FELDENE,

GLUCOTROL, PROCARDIA XL,

NORVASC, CARDURA, DIFLUCAN,

ZOLOFT, and ZITHROMAX.

The company may locate production

of three new products, VIAGRA

treatment for erectile dysfuntion

(HTSUS 3004.90.9040), TIKOSYN antiarrhythmia treatment (HTSUS

3004.90.9020) and eletripten migraine

treatment (HTSUS 3004.90.9040) at the

Barceloneta facility contingent upon

receiving approval for subzone

procedures at the plant. Foreign-sourced

materials will account for, on average,

86 percent of materials value, and

include items from the following

categories:

Aromatic ethers and their derivatives

HTSUS 2909.30.4000 10.3%

Aromatic monoamines and their

derivatives, salts

HTSUS 2921.49.4500 10.7%

Organo-sulfur compounds

HTSUS 2930.90.9050 3.7%

Heterocyclic compounds with nitrogen

hetero-atoms(s):

HTSUS 2933.19.9000 6.8%

HTSUS 2933.59.5300 6.6%

HTSUS 2933.59.7000 10.7%

HTSUS 2933.90.7900 10.7%

HTSUS 2933.90.9000 3.7%

The company may also purchase from

abroad other ingredients and materials

in the following general categories:

gums, starches, waxes, vegetable

extracts, mineral oils, sugars, empty

capsules, protein concentrates, prepared

animal feed, mineral products,

inorganic acids, chlorides, clorates,

sulfites, sulfates, phosphates, cyanides,

silicates, radioactive chemicals, rareearth metal compounds, hydroxides,

hydrazine and hydroxylamine,

chlorides, phosphates, carbonates,

hydrocarbons, alcohols, phenols, ethers,

epoxides, acetals, aldehydes, ketone

function compounds, mono- and

polycarboxylic acids, phosphoric esters,

amine-, carboxymide, nitrile- and

oxygen-function compounds,

heterocyclic compounds, sulfonamides,

insecticides, rodenticides, fungicides

and herbicides, fertilizers, vitamins,

hormones, antibiotics, gelatins,

enzymes, pharmaceutical glaze,

essential oils, albumins, gelatins,

activated carbon, residual lyes, acrylic

polymers, color lakes, soaps and

detergents, various packaging and

printing materials, medicaments,

pharmaceutical products, and

instruments and appliances used in

medical sciences. Some 10 percent of

production may be exported.

Zone procedures would exempt Pfizer

from Customs duty payments on foreign

materials used in production for export.

On domestic sales, the company would

be able to choose the duty rates that

apply to the finished products (dutyfree). The duty rates on foreign-sourced

items range from duty-free to 18.6

percent. At the outset, zone savings

would primarily involve choosing the

finished product duty rate on VIAGRA,

TIKOSYN and eletripten (duty-free),

rather than the rates for their foreign

components listed above (duty rates

ranging from 3.7% to 10.7%). The

application indicates that the savings

from zone procedures will help improve

the plant’s international

competitiveness.

In accordance with the Board’s

regulations, a member of the FTZ Staff

has been designated examiner to

investigate the application and report to

the Board.

Public comment is invited from

interested parties. Submissions (original

and 3 copies) shall be addressed to the

Board’s Executive Secretary at the

address below. The closing period for

their receipt is June 22, 1998. Rebuttal

comments in response to material

submitted during the foregoing period

may be submitted during the subsequent

15-day period (to July 6, 1998).

A copy of the application and

accompanying exhibits will be available

for public inspection at each of the

following locations:

U.S. Department of Commerce Export

Assistance Center, Plaza Torre, 525

F.D. Roosevelt Ave., Suite 905, San

Juan (Hato Rey), Puerto Rico 00918

Office of the Executive Secretary,

Foreign-Trade Zones Board, U.S.

Department of Commerce, Room

3716, 14th and Pennsylvania Avenue,

NW., Washington, DC 20230

Dated: April 14, 1998.

Dennis Puccinelli,

Acting Executive Secretary.

[FR Doc. 98–10572 Filed 4–20–98; 8:45 am]

BILLING CODE 3510–DS–P